RU2005141060A - Метаболит кветиапина - Google Patents
Метаболит кветиапина Download PDFInfo
- Publication number
- RU2005141060A RU2005141060A RU2005141060/15A RU2005141060A RU2005141060A RU 2005141060 A RU2005141060 A RU 2005141060A RU 2005141060/15 A RU2005141060/15 A RU 2005141060/15A RU 2005141060 A RU2005141060 A RU 2005141060A RU 2005141060 A RU2005141060 A RU 2005141060A
- Authority
- RU
- Russia
- Prior art keywords
- symptom
- condition
- yldibenzo
- thiazepine
- piperazin
- Prior art date
Links
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title 1
- 229960004431 quetiapine Drugs 0.000 title 1
- 208000024891 symptom Diseases 0.000 claims 24
- JLOAJISUHPIQOX-UHFFFAOYSA-N Norquetiapine Chemical compound C1CNCCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 JLOAJISUHPIQOX-UHFFFAOYSA-N 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 208000020925 Bipolar disease Diseases 0.000 claims 11
- 208000019901 Anxiety disease Diseases 0.000 claims 7
- 206010026749 Mania Diseases 0.000 claims 7
- 208000019022 Mood disease Diseases 0.000 claims 7
- 208000028017 Psychotic disease Diseases 0.000 claims 7
- 230000036506 anxiety Effects 0.000 claims 7
- 208000028683 bipolar I disease Diseases 0.000 claims 7
- 208000025307 bipolar depression Diseases 0.000 claims 7
- 201000000980 schizophrenia Diseases 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 239000012458 free base Substances 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436503P | 2003-07-02 | 2003-07-02 | |
| US60/484,365 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005141060A true RU2005141060A (ru) | 2006-07-27 |
Family
ID=33563981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005141060/15A RU2005141060A (ru) | 2003-07-02 | 2004-06-28 | Метаболит кветиапина |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050026900A1 (https=) |
| EP (1) | EP1644005B1 (https=) |
| JP (1) | JP2007516193A (https=) |
| KR (1) | KR20060082037A (https=) |
| CN (1) | CN1816339B (https=) |
| AR (1) | AR045004A1 (https=) |
| AT (1) | ATE477803T1 (https=) |
| AU (1) | AU2004253334A1 (https=) |
| BR (1) | BRPI0412127A (https=) |
| CA (1) | CA2531284A1 (https=) |
| DE (1) | DE602004028739D1 (https=) |
| ES (1) | ES2349091T3 (https=) |
| IL (1) | IL172616A0 (https=) |
| IS (1) | IS8283A (https=) |
| MX (1) | MXPA05013869A (https=) |
| NO (1) | NO20060556L (https=) |
| RU (1) | RU2005141060A (https=) |
| TW (1) | TW200509944A (https=) |
| UY (1) | UY28400A1 (https=) |
| WO (1) | WO2005002586A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL164155A0 (en) * | 2002-03-20 | 2005-12-18 | Teva Pharma | Crystalline forms of quetiapine hemifumarate |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| PT1696931E (pt) | 2003-12-22 | 2009-06-12 | Acadia Pharm Inc | Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
| AU2006231497A1 (en) * | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
| US7687622B2 (en) * | 2005-04-14 | 2010-03-30 | Teva Pharmaceutical Industries, Ltd | Process for preparing quetiapine fumarate |
| WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
| WO2008079848A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab (Se/Se) | Compounds and uses thereof |
| WO2007062337A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Crystalline forms |
| WO2007062339A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| WO2008116144A1 (en) * | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Methods of treating mood disorders |
| JP2009516705A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 塩の形態 |
| US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| WO2007062338A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| JP2010531292A (ja) * | 2006-12-20 | 2010-09-24 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
| EP2120563A4 (en) * | 2006-12-20 | 2011-04-27 | Astrazeneca Ab | CONNECTIONS AND ITS USES |
| US8715699B2 (en) | 2009-12-31 | 2014-05-06 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| WO2011112657A1 (en) | 2010-03-11 | 2011-09-15 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| WO2000010572A1 (en) * | 1998-08-18 | 2000-03-02 | Sepracor Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
-
2004
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Withdrawn
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en not_active Ceased
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-06-28 EP EP04743131A patent/EP1644005B1/en not_active Expired - Lifetime
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050026900A1 (en) | 2005-02-03 |
| CA2531284A1 (en) | 2005-01-13 |
| NO20060556L (no) | 2006-04-03 |
| WO2005002586A8 (en) | 2006-02-09 |
| IL172616A0 (en) | 2006-04-10 |
| DE602004028739D1 (de) | 2010-09-30 |
| BRPI0412127A (pt) | 2006-08-15 |
| MXPA05013869A (es) | 2006-02-28 |
| JP2007516193A (ja) | 2007-06-21 |
| IS8283A (is) | 2006-02-01 |
| KR20060082037A (ko) | 2006-07-14 |
| AU2004253334A1 (en) | 2005-01-13 |
| WO2005002586A1 (en) | 2005-01-13 |
| TW200509944A (en) | 2005-03-16 |
| ATE477803T1 (de) | 2010-09-15 |
| EP1644005A1 (en) | 2006-04-12 |
| UY28400A1 (es) | 2005-01-31 |
| ES2349091T3 (es) | 2010-12-27 |
| AR045004A1 (es) | 2005-10-12 |
| CN1816339B (zh) | 2010-12-15 |
| CN1816339A (zh) | 2006-08-09 |
| EP1644005B1 (en) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005141060A (ru) | Метаболит кветиапина | |
| JP2007516193A5 (https=) | ||
| GEP20125405B (en) | Amino-heterocyclic compounds | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| GEP20104959B (en) | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| ATE454378T1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| BR0206434A (pt) | Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente | |
| BR0203274A (pt) | teres aromáticos de difluorometilenos | |
| MX2011011489A (es) | Derivados de isoxazol-piridina. | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| ATE253918T1 (de) | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel | |
| RU2014122858A (ru) | Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| MXPA05013628A (es) | Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3. | |
| JP2007509960A5 (https=) | ||
| ATE439363T1 (de) | Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides | |
| ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
| EE200100553A (et) | Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks | |
| RU2003127718A (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| MX2007007472A (es) | Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c. | |
| JP2005513036A5 (https=) | ||
| ATE445401T1 (de) | Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin | |
| AU2003257589A1 (en) | Remedy for integration dysfunction syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20070712 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20070726 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090303 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090303 |